Nanotechnology Now - Press Release: Lumera Corporation and Plexera Bioscience Announce Speakers at Three Conferences

Home > Press > Lumera Corporation and Plexera Bioscience Announce Speakers at Three Conferences

Abstract:
Lumera Corporation (NASDAQ:LMRA), a leader in the field of photonic communications, announced today that Dr. Raluca Dinu, Vice President - Electro-Optic Business Unit, will speak at the Global Crown Capital Nanotechnology conference on November 7 in Palo Alto, CA. She is also scheduled to speak at the 30th Annual Paulson Investment Westergaard conference in New York on November 13. In both cases, Dinu will give an overview of Lumera Corporation's electro-optic capabilities and products.

Lumera Corporation and Plexera Bioscience Announce Speakers at Three Conferences

BOTHELL, WA | Posted on October 24th, 2007

Plexera Bioscience LLC, a wholly owned subsidiary of Lumera, announced that Dr. Joe Vallner, Chairman and CEO of Plexera, will be a speaker at the Acumen Biofin Rodman & Renshaw 9th Annual Healthcare conference in New York on November 5. Plexera also announced that Dr. Timothy Londergan, President and COO, will give an overview of Plexera at the 30th Annual Westergaard conference in New York on November 13.

Additional information on the Global Crown conference can be obtained at http://www.globalcrowncapital.com/ ; on the Acumen Biofin conference at http://www.rodmanandrenshaw.com/conferences?id=6 ; and on the Westergaard conference at http://guest.cvent.com/EVENTS/Info/Summary.aspx?e=a0ddf4ee-9c19-4885-beb7-63f886c15d33 .

####

About Lumera Corporation
Lumera is a leader in the field of photonic communications. The company designs electro-optic components based on proprietary polymer compounds for the communications/computing industries.

About Plexera Bioscience LLC

Plexera Bioscience LLC was established in July of 2007 as a wholly owned subsidiary of Lumera Corporation (NASDAQ:LMRA) and is focused on providing the life sciences market with tools, content, and methods to simplify and accelerate proteomic discovery for therapeutic antibodies as well as predictive biomarkers.

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.

For more information, please click here

Contacts:
Lumera Corporation
(Investor Relations)
Hélčne F. Jaillet, Ph.D, 425-398-6546
or
The Summit Group Communications
(Media)
Todd Wolfenbarger, 801-595-1155
801-244-9600 cell

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: